Weekly Recap | Abbott Laboratories -1.28%, busy approvals but lagging the market

LongbridgeAII'm LongbridgeAI, I can summarize articles.

The Week

Abbott Laboratories (ABT) fell 1.28% this week to close at $108.52, underperforming the S&P 500 by about 3.79 percentage points as the index rose 2.51%. Trading was choppy: the stock opened at $110.88 on Monday (9 Nov), touching a weekly high of $111.01 before sliding to $106.89 on Thursday (12 Nov), then recovering to $108.52 by Friday’s close. Weekly amplitude was 3.72%, with average daily volume near 8.1m shares, roughly in line with the 60-day median.

Key Events

Abbott’s week was heavy on cardiovascular and diagnostics news. On Monday, coverage centred on a heart device approval. On Tuesday (10 Nov), the company launched Oncodetect, announced FDA approval and CE mark for an implantable cardioverter-defibrillator lead designed to work with the heart’s natural electrical system, and began rolling out a three-virus home test for COVID-19 and flu A/B at over 1,800 Canadian pharmacies. Wednesday’s (11 Nov) coverage noted the CRC approval milestone lifting Q3 results alongside commercial launches and pipeline expansion. Friday (13 Nov) brought a CES 2027 preview of health innovation and a new wearable technology white paper. The share price moved lower through Thursday before stabilising, with no direct causal link to these announcements in the week’s tape.

Analyst Ratings

Coverage totals 29 brokers: 18 rate it buy, 5 overweight, 5 hold, and 1 has no opinion; there are no underweight or sell ratings. The consensus recommendation is buy, with a consensus target of $118.91, about 9.57% above the spot price of $108.52. Targets range from $100 to $130, indicating wide dispersion. Abbott ranks 7th within its 142-company medical devices sector.

The Week Ahead

Macro data dominates the calendar next week. Monday (16 Nov) brings the Empire State manufacturing index with a prior of 25.5 and forecast of 18. Tuesday (17 Nov) is busy: import price index, retail sales, retail sales ex-autos, industrial production, and the NAHB housing market index. Retail sales carry a prior of 0.8 and forecast of 0.2; ex-autos prior of 0.9 with forecast of 0.4. Abbott has no scheduled earnings release, so the focus shifts to how macro prints shape sentiment across the broader market and healthcare names.

In Short

The week paired heavy product approval and launch news with lagging share price action. Broker sentiment remains favourable on a consensus basis, with a target roughly 10% above spot, though individual targets are scattered. On the latest trading day, large and medium lots were net modest buyers while small lots sold; valuation sits near 40x P/E and 3.7x P/B. What to watch next is how quickly Abbott converts its pipeline approvals into commercial traction, and whether macro data boosts or dampens the healthcare sector’s tone.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.

Source: Weekly Review The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.